Vivos Nevada Referrals Surge 212% Ahead of New Henderson Facility Opening
VVOS is trading near its 52-week low of $0.26 (7.6% above the low) on light trading volume (0.1× avg).
Summary
Vivos Therapeutics reported a 212% jump in average weekly new patient referrals at its Nevada Sleep & Airway Medicine Centers over the past six weeks, with total referrals up nearly five-fold since June 1. The company also announced the August 27 grand opening of an 8,100 sq. ft. Henderson facility, where collections hit record highs in two of the past three months. This operational momentum comes as Vivos faces a going concern warning, $1.8M cash, and a $5.5M Q2 loss, making revenue growth critical. Management expects the new facility and recent personnel changes to drive further revenue gains, though conversion of referrals to paying patients remains a key risk. The stock trades at $0.28 with a $5.6M market cap, so any sustained revenue inflection could materially move shares.
At the time of this announcement, VVOS was trading at $0.28 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $5.6M. The 52-week trading range was $0.26 to $5.12. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.